

Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2022

<https://marketpublishers.com/r/DD788249528EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: DD788249528EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Understanding

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview

Prostaglandin D2 receptor is a 395 amino acid, 43 kDa G-protein-coupled receptors. PGD2 is released following activation of the immune system, which can be either non-allergen- or allergen-dependent. Binding of PGD2 to the DP2 receptor on immune cells induces a myriad of pro-inflammatory downstream effects, which significantly contribute to the recruitment, activation and/or migration of TH2 cells, ILC2, and eosinophils. PGD2 produced by mast cells might provide an essential link between the early phase and late-phase allergic responses and such antagonism of PGD2 provides an attractive

target for therapeutic intervention. Several selective, orally active, DP2 receptor antagonists are being developed for the treatment of allergic disorders.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence DP1 Receptor (Prostaglandin D2 receptor) Antagonist R&D. The therapies under development are focused on novel approaches for DP1 Receptor (Prostaglandin D2 receptor) Antagonist.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs Chapters

This segment of the DP1 Receptor (Prostaglandin D2 receptor) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs

BGE-175: BioAge Labs

BGE-175 is an orally administered small-molecule based inhibitor of the prostaglandin D2 (PGD2) DP1 signaling pathway. The drug is in phase II clinical studies for the treatment of Covid-19 infections. In January 2021, Shionogi announced that it has concluded a license agreement with BioAge Labs. With this agreement, Shionogi grants BioAge exclusive U.S. and European rights to develop and commercialize BGE-175 for COVID-19 treatment. In addition, Shionogi grants BioAge exclusive rights to negotiate a license for additional indications. Under this agreement, Shionogi will receive an upfront payment and milestones according to future development, as well as royalties on sales if BGE-175 is successfully commercialized.

SLS 008: Seelos Therapeutics

SLS 008 is a small molecule, orally-bioavailable antagonist of the prostaglandin D2 receptor. The drug is in preclinical studies for the treatment of asthma, atopic dermatitis,

and oesophagitis.

Further product details are provided in the report.....

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on DP1 Receptor (Prostaglandin D2 receptor) Antagonist

There are approx. 8+ key companies which are developing the DP1 Receptor (Prostaglandin D2 receptor) Antagonist. The companies which have their DP1 Receptor (Prostaglandin D2 receptor) Antagonist drug candidates in the most advanced stage, i.e. Phase II include, BioAge Labs.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products

have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs.

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Insights

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs?

How many DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for DP1 Receptor (Prostaglandin D2 receptor) Antagonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for DP1 Receptor (Prostaglandin D2 receptor) Antagonist and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

CSPC ZhongQi Pharmaceutical Technology

BioAge Labs

Novartis

Chiesi Farmaceutici

Idorsia Pharmaceuticals

Seelos Therapeutics

Sunshine Lake Pharma

Key Products

CSPCHA-115

Asapiprant

Fevipirant

Timapirant

ACT-774312

SLS 008

Litapirant

Contents

Introduction

Executive Summary

DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration

DP1 Receptor (Prostaglandin D2 receptor) Antagonist – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- DP1 Receptor (Prostaglandin D2 receptor) Antagonist companies' collaborations, Licensing, Acquisition -Deal Value Trends

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Fevipiprant: Novartis

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

BGE-175: BioAge Labs

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

CSPCHA-115: CSPC ZhongQi Pharmaceutical Technology

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

SLS 008: Seelos Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Products

DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Unmet Needs

DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Market Drivers and Barriers

DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Future Perspectives and

Conclusion

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Analyst Views

DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Prostaglandin D2 receptor Antagonist

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Prostaglandin D2 receptor Antagonist

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/DD788249528EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD788249528EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970